Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRBN | Q96SW2 | 12/20 | 0.43 |
| ▸ | DDB1 | Q16531 | 11/20 | 0.43 |
| ▸ | CHRM4 | P08173 | 2/20 | 0.34 |
| ▸ | HRH2 | P25021 | 1/20 | 0.33 |
| ▸ | HRH1 | P35367 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | POLB | P06746 | 1/20 | 0.32 |
| ▸ | CCR5 | P51681 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30225550 | 0.93 | CRBN (0.43) | CRBNDDB1CHRM4HRH2HRH1 | |
| SCHEMBL21070587 | 0.87 | DDB1 (0.45) | CRBNDDB1KDM4ECCR5 | |
| SCHEMBL21998134 | 0.84 | CRBN (0.48) | CRBNDDB1CHRM4HRH2HRH1 | |
| SCHEMBL26635060 | 0.83 | DDB1 (0.46) | CRBNDDB1KDM4ECCR5 | |
| SCHEMBL21070862 | 0.83 | CRBN (0.52) | CRBNDDB1 | |
| Hydrochloric Acid SCHEMBL30043421 | 0.82 | CRBN (0.51) | CRBNDDB1 | |
| SCHEMBL23832693 | 0.80 | CRBN (0.48) | CRBNDDB1IRAK4 | |
| SCHEMBL21997665 | 0.80 | DDB1 (0.48) | CRBNDDB1CHRM4CCR5 | |
| SCHEMBL21997604 | 0.80 | DDB1 (0.45) | CRBNDDB1CCR5 | |
| SCHEMBL21997673 | 0.80 | GPR119 (0.44) | CRBNDDB1CCR5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11318205-B1 | IRAK degraders and uses thereof | KYMERA THERAPEUTICS, INC. (US) | 2022-05-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11318205-B1 | IRAK degraders and uses thereof | IRAK2, IRAK3, IRAK1 | CRBN 187/4885DDB1 1267/4885CHRM4 4468/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.